Shared inflammatory genes help explain poorer outcomes and point to potential new avenues for targeted treatment
New research shows that the same genes are active in pancreatic cancer, obesity and diabetes, helping to explain why people with metabolic disease often face poorer cancer outcomes and pointing to future ways to predict recurrence and develop more targeted treatments.
In a study published in Cancer Medicine, researchers from the University of Birmingham, including experts supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre: Birmingham, set out to test whether genes already linked to pancreatic cancer recurrence also behave differently in metabolic disease.
Using large human and mouse genetic datasets, single cell analysis of pancreatic tumours, and laboratory testing of human tissue, they found consistent evidence that the same genes are active across both conditions.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterised by late diagnosis, limited treatment options and a high risk of relapse, with around 80% of patients experiencing recurrence even after surgery. Obesity and type 2 diabetes are both known risk factors for PDAC, but the biological reasons for this link have not been fully understood.
the same genes and inflammatory pathways are active in both metabolic disease and pancreatic cancer
Dr Animesh Acharjee, Associate Professor of Integrative Analytics and AI at the University of Birmingham and senior author of the study, said: “We know that people with obesity or diabetes tend to have worse outcomes from pancreatic cancer, but the biological reasons have not been clear.
"Our study shows that the same genes and inflammatory pathways are active in both metabolic disease and pancreatic cancer, which helps explain this link and points to new opportunities for identifying high‑risk patients and developing more targeted treatments.”
Across all stages of the study, the researchers consistently observed increased activity of six genes – ITGAM, PECAM1, CCL5, STAT1, STAT2 and CD44 – previously associated with pancreatic cancer recurrence. These genes drive inflammatory and immune pathways and appear to form a shared biological link between metabolic disease and pancreatic cancer.
The study also identified a specific immune cell population inside pancreatic tumours where these pathways are particularly active, suggesting that inflammation linked to obesity or diabetes may help create conditions that support tumour growth and recurrence.
To investigate shared biological mechanisms between pancreatic cancer and metabolic disease, the team used an integrative, multi‑stage approach that combined large‑scale analysis of human and mouse genetic data with detailed tumour‑level and laboratory validation.
First, they analysed publicly available genetic datasets from humans and mice to examine how key pancreatic cancer‑associated genes behave in healthy individuals compared with those with obesity, allowing them to identify consistent patterns across species.
They then analysed single‑cell data from human pancreatic tumours to examine activity within the tumour microenvironment. This revealed a specific group of immune cells showing high levels of inflammatory activity linked to both metabolic dysfunction and cancer progression.
Finally, the researchers validated their key findings in human tissue samples in the laboratory, confirming that several of the same genes were more active in obesity‑associated contexts.
Professor Simon Jones, Professor in Musculoskeletal Ageing at the University of Birmingham and Theme Lead for the NIHR Biomedical Research Centre: Birmingham Sarcopenia and Multimorbidity research theme, said: “This study highlights how chronic inflammation and metabolic dysfunction can intersect with cancer biology. Understanding these shared mechanisms is essential if we are to improve outcomes for patients who are living with multiple long‑term conditions alongside cancer.”
This study was funded by the Medical Research Council and Arthritis UK, and was delivered through the NIHR Biomedical Research Centre: Birmingham.
For media enquiries and more information please contact Tim Mayo, Press Office, University of Birmingham, tel: +44 (0)7815 607 157.
‘Linking Targeted Pancreatic Cancer Genes with Metabolic Disorders: A Cross-species Translational Pathway’ –Nath D, Ditchfield C, Price J, Sivakumar S, Jones SW, Acharjee A is published in Cancer Medicine.
The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, educators and more than 40,000 students from over 150 countries.
England’s first civic university, the University of Birmingham is proud to be rooted in of one of the most dynamic and diverse cities in the country. A member of the Russell Group and a founding member of the Universitas 21 global network of research universities, the University of Birmingham has been changing the way the world works for more than a century.
The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:
The NIHR Biomedical Research Centre: Birmingham (BRC) is part of the NIHR and hosted by University Hospitals Birmingham NHS Foundation Trust (UHBFT) in partnership with the University of Birmingham (UoB). The BRC’s research programme focuses on inflammation and the diagnosis, prevention and treatment of its associated long-term illnesses.
Associate Professor
Staff profile of Dr Animesh Acharjee, Associate Professor, Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham
Professor in Musculoskeletal Ageing
Staff profile for Professor Simon Jones, Professor in Musculoskeletal Ageing, Department of Inflammation and Ageing, College of Medicine and Health, The University of Birmingham.
